- Trial phase
- Filed/PDUFA (NDA submitted)
- Time to market
- If the FDA accepts the NDA for filing, a standard review would take 10 months from filing acceptance, with a potential PDUFA date in late 2027. Priority review (if granted) could shorten this to 6-8 months. The FDA has 60 days from the October 28 submission to decide on filing acceptance.
- Why 7/10
- The next hard catalyst is the FDA's decision on whether to accept the NDA for filing, due within approximately 60 days (by late December 2026). Remibetadex is the company's lead late-stage asset and primary value driver, though Rafael Holdings also holds interests in other early-stage pharma and medical device companies. The Phase 3 primary endpoint miss creates significant approval risk, making this a high-concentration binary event.
The next catalyst is the FDA's filing decision within approximately 60 days (by late December 2026). If the NDA is accepted, a PDUFA target action date will be assigned. If rejected, the stock could face significant downside given the Phase 3 primary endpoint miss. Watch for any financing announcements given the $22.1M cash balance and ongoing burn rate.
Price Chart
Executive Summary
Remibetadex (Trappsol Cyclo) is Rafael Holdings' lead asset for Niemann-Pick Disease Type C (NPC), an ultra-rare fatal genetic disorder. A New Drug Application was submitted to the FDA on October 28, 2026, just one day before today's report date. The submission follows a pivotal Phase 3 trial that missed its primary endpoint (p=0.19) but showed statistically significant benefit in a prespecified subgroup and an overall survival analysis. The FDA has 60 days to decide whether to accept the NDA for review. Two competing NPC drugs were already approved in September 2024, creating a crowded rare-disease market. With $22.1M in cash and a quarterly burn rate around $8.5M, the company faces both regulatory and financing risk.
How It Works
Remibetadex is a synthetic sugar ring molecule (a cyclodextrin) that acts like a cholesterol sponge. In Niemann-Pick Disease Type C, a defective protein (NPC1) cannot move cholesterol out of cells, causing toxic buildup. Remibetadex substitutes for this missing function: its hollow core traps cholesterol, allowing it to be transported out of cells and excreted from the body. It is administered intravenously every two weeks.
Trial Status
The pivotal Phase 3 TransportNPC study (CTD-TCNPC-301) enrolled 94 NPC patients aged 3-70 years, randomized 2:1 to remibetadex 2000 mg/kg IV every 2 weeks or placebo for 96 weeks. The primary endpoint (change in 4-domain NPC Clinical Severity Scale at Week 96) was not met (p=0.19). A prespecified subgroup of 78 patients on background miglustat/leucine showed a statistically significant 71% slowing of disease progression (p=0.046). An overall survival analysis in infantile-onset patients showed an 85% mortality risk reduction versus registry controls (p=0.044). Serious adverse events were higher with remibetadex (35.9%) versus placebo (16.7%).
The Two-Sided Case
Upcoming Catalysts
- FDA filing decision on the NDA within ~60 days (by late December 2026)
- If accepted, assignment of a PDUFA target action date and potential Priority Review designation
- Q4 FY2026 earnings report scheduled for November 2, 2026
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Rafael Holdings, Inc. PRESS-RELEASE RFL ·Originating report